西来帕格治疗系统性硬化症继发雷诺现象的随机安慰剂对照II期研究:疗效与安全性
该随机、安慰剂对照II期研究纳入系统性硬化症相关雷诺现象患者,按1:1随机分配至安慰剂组(n=38)或西来帕格组(n=36),个体化剂量滴定(最大1,600 μg每日两次)3周。主要终点维持期每周平均雷诺现象发作次数经贝叶斯负二项模型分析,安慰剂组与西来帕格组无显著差异(校正后平均治疗差异为3.4,偏向安慰剂)。西来帕格未减少雷诺现象发作次数,安全性特征与既往报道相似。
要点
- 西来帕格未显著减少系统性硬化症相关雷诺现象的每周平均发作次数(校正后平均治疗差异3.4,偏向安慰剂)。
- 83.3%患者的西来帕格个体化维持剂量≤800 μg每日两次。
- 西来帕格组100%报告至少1例不良事件,91.7%报告至少1例前列环素相关不良事件。
核心结论
- 与安慰剂相比,西来帕格未减少雷诺现象发作次数,安全性特征与既往报道相似。
研究设计与样本
- 随机、安慰剂对照II期研究,系统性硬化症相关雷诺现象患者按1:1随机分配至安慰剂组(n=38)或西来帕格组(n=36),个体化剂量滴定3周(最大1,600 μg每日两次)。
主要发现
- 维持期每周平均电子日记记录的雷诺现象发作次数:安慰剂组(n=32)维持期14.2次、基线周21.5次,西来帕格组(n=27)维持期18.0次、基线周22.4次,校正后平均治疗差异为3.4,偏向安慰剂,无显著差异。
- 雷诺现象条件评分或发作持续时间均未观察到显著治疗效果。
- 双盲期安慰剂组86.8%、西来帕格组100%报告至少1例不良事件;分别有55.3%和91.7%报告至少1例前列环素相关不良事件。
关键数值与推荐
- 83.3%患者的西来帕格个体化维持剂量≤800 μg每日两次。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the effect of selexipag, an oral, selective IP prostacyclin receptor agonist, on the frequency of attacks of Raynaud's phenomenon (RP) in patients with systemic sclerosis (SSc). METHODS: Patients with SSc-related RP were randomized 1:1 to placebo (n = 38) or selexipag (n = 36) in individualized doses (maximum of 1,600 μg twice daily) during a 3-week titration period. The primary end point was the weekly average number of RP attacks during the study maintenance period, analyzed using a Bayesian approach with a negative binomial model adjusted for baseline number of RP attacks. Other outcome measures included Raynaud's Condition Score (RCS), RP attack duration, and treatment-emergent adverse events (AEs). RESULTS: Baseline characteristics were comparable between treatment groups. For 83.3% of patients, the individualized maintenance dosage of selexipag was ≤800 μg twice daily. No significant difference was observed between placebo and selexipag in weekly average number of electronic diary (eDiary)-recorded RP attacks during the maintenance period (14.2 attacks during the maintenance period and 21.5 attacks during the baseline week in the placebo group [n = 32] versus 18.0 attacks during the maintenance period and 22.4 attacks during the baseline week in the selexipag group [n = 27]; adjusted mean treatment difference of 3.4 in favor of placebo). No significant treatment effect was observed on RCS or RP attack duration. In the double-blind period, 86.8% of placebo-treated patients and 100% of selexipag-treated patients reported ≥1 AE; 55.3% and 91.7%, respectively, reported ≥1 prostacyclin-associated AE. CONCLUSION: Treatment with selexipag did not reduce the number of RP attacks compared with placebo. The safety profile of selexipag was similar to that previously reported. This study provides important information about the feasibility of eDiary reporting of RP attacks in clinical trials.
引用
- Denton CP, Hachulla É, Riemekasten G, et al. Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo-Controlled, Phase II Study. Arthritis Rheumatol. 2017. PMID: 29193819. doi:10.1002/art.40242
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。